Evidence map›Paper›PMID 28529604›Full record

ArticleJournal of Cancer2017

DICER1 regulates endometrial carcinoma invasion via histone acetylation and methylation.

Bilan Li, Wen Lu, Junjie Qu, Yongli Zhang, Xiaoping Wan

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. MicroRNA-21 promotes endometrial carcinoma proliferation and invasion by targeting PTEN.International journal of clinical and experimental pathology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bilan LiDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University, School of Medicine, Shanghai, P.R. China.
Wen LuDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University, School of Medicine, Shanghai, P.R. China.
Junjie QuDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University, School of Medicine, Shanghai, P.R. China.
Yongli ZhangDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University, School of Medicine, Shanghai, P.R. China.
Xiaoping WanDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University, School of Medicine, Shanghai, P.R. China.
Shanghai First Maternity and Infant Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial carcinoma (EC) is one of the most common gynecologic malignancy, but molecular mechanisms of the development and progression of EC remain unclear. Here we showed that the expression of DICER1 was negatively associated with the level of histone methylation, histone acetylation and PRC2 components SUZ12 and EZH2 in EC cells. In addition, knockdown of DICER1 significantly downregulated miR-200b and let-7i, which may then regulate their targets SUZ12 and EZH2. Furthermore, knockdown of DICER1 remarkably suppressed the expression of epithelial cell marker E-cadherin, induced the expression of mesenchymal cell marker Vimentin, and promoted the invasion of EC cells. In conclusion, our data suggest that DICER1 suppresses SUZ12 and EZH2 via affecting their upstream miRNA synthesis, and inhibits epithelial-mesenchymal transition(EMT) and invasion of EC cells via histone modification.

Indexed as

DICER1endometrial carcinomaepithelial-mesenchymal transitionhistoneacetylationhistone methylation

Identifiers

PMID28529604
PMCPMC5436244
OpenAlexW2595008823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.